Beschreibung

I help companies navigate M&A transactions and make better investment decisions through rigorous financial analysis. With buy-side experience at a leading PE-backed pharma platform (Astorg portfolio), I bring hands-on deal execution skills from screening through IC-ready deliverables.

What I deliver:

- DCF and trading comps valuations with scenario/sensitivity analysis

- CIM reviews, strategic fit assessments, and No-Go recommendations

- Working capital analysis (DSO/DIO/DPO), EV-to-equity bridges, and pricing guardrails

- Investment memos and IC-ready materials for senior decision-makers

- Market and supply/demand assessments for target industries

My background spans corporate development, alternative investment valuation (IFRS 13/IPEV), and financial analysis across Pharma/CDMO, PE, and financial services. I hold an MSc in Finance (Aarhus University), am pursuing an MBA at Frankfurt School, and have passed CFA Level II.

Tools: Excel (advanced, VBA/macros), PowerPoint, Bloomberg, S&P Capital IQ, PitchBook, Python.

Branchenexpertise

Sprachen

Dänisch
Muttersprachlich oder zweisprachig
Englisch
Verhandlungssicher
Deutsch
Verhandlungssicher
Schwedisch
Konversationssicher
Norwegisch
Konversationssicher

Arbeitsortpräferenzen

Vor Ort möglich

Frankfurt am Main (bis zu 50 km)

CordenPharma (Astorg Portfolio)
Corporate Development and M&A, MBA Associate
PHARMAZEUTISCHE INDUSTRIE
August 2025 - Heute (10 Monate)
Plankstadt, BW, Germany
• • Led the buy-side valuation workstream. Built DCFs and trading comps from CIM inputs and ran sensitivities across WACC, margin ramp, and CapEx phasing to set valuation ranges and pricing guardrails (incl. a preliminary walk-away price).
• •Assessed business fundamentals and strategic fit early to identify deal-breakers and prioritize diligence on the right targets.
• • Built working-capital benchmarks by calculating and benchmarking DSO/DIO/DPO to derive a normalized NWC for purchase price adjustments. Built the EV-to-equity bridge (net debt and NWC).
• • Built a global peptide API supply/demand assessment across pharma/biotech and CDMOs. Modeled capacity ramp by site and over time (scale-up and ramp-up) to map bottlenecks and capacity gaps across demand scenarios.

Selected deal experience (buy-side, confidential)
• • Peptide-focused CDMO (Pre-LOI): built the initial valuation (DCF + trading comps). Normalized base/downside cases using achievable output (incl. yield/waste), margin ramp, CapEx ramp/normalization, and normalized NWC. Prepared an IC/internal approval pack with valuation range (base/downside) and a data/diligence request list for management sign-off.
• • Diversified CDMO platform (No-Go): conducted a CIM review and fit assessment. Identified strategic scope misalignment (non-core modality) and material complexity risks across a multi-site operating model and QA harmonization. Delivered a documented No-Go recommendation.
Due Diligence Business Valuation M&A Financial Modeling
The Halal Shack
Corporate Development Consultant
GASTRONOMIE
Mai 2024 - Juni 2025 (1 Jahr und 1 Monat)
Dallas, TX, USA
• • Built DCF-based business cases for market entry and site expansion supporting ~USD 12m in CapEx planning.
• • Led demographic analysis and pre-opening diligence across 20+ sites, enabling 8 on-time launches. Developed financial projections, assessed site-level P&L economics, and presented investment recommendations to founders and stakeholders.
Due Diligence Businessplan-Entwicklung Business Valuation Financial Modeling Investorendokumente
BNY Mellon
Senior Analyst, Valuation & Due Diligence, Alternative Investments
BANKEN & VERSICHERUNGEN
August 2021 - April 2024 (2 Jahre und 8 Monate)
Copenhagen, Denmark
• • Performed independent fair value analysis of 30+ alternative funds and illiquid investments under IFRS 13 and IPEV principles. Validated investment manager valuations using market data, comparable assets, and model-based valuations (cashflow- or rate-based, depending on the instrument).
• • Reviewed key assumptions (discount rates/spreads, terminal value and liquidity adjustments such as DLOM) and challenged outliers with evidence requirements for changes in reported fair value.
• • Delivered valuation conclusions and driver attribution for internal stakeholders and client-facing materials.
Business Valuation Financial Modeling